Skip to content
MedCompare

Mifepristone

Women's Health
Save $13,487/mo
686× cheaper

KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

United States
$13,507
per month
India
$20
per month
You save
$13,487
99.85% cheaper in India
10.4K US scripts/yr$140.3M potential annual savings$140.5M US spend/yr
Building 3D structure…
Drag to rotate · 3D structureC29H35NO2

SMILES: CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O

Compare the price
US price$13,507per month
India price$20per month
You save$13,48799.85% less

Based on 30 units per month. US $450.23 vs India $0.66 per unit.

Total over 1 periodSave $13,487$13,507 → $20
Is travelling to India worth it?

The savings here are large enough that a trip may still come out ahead. Adjust the numbers to your own situation — every value is an editable estimate.

Medicine savings over 6 months
$80,923
Estimated travel cost
− $2,300
Net savings after travel
$78,623

Even after travel, you could come out ahead by about $78,623.

Assumptions: medicine savings = (US − India monthly price) × months. Travel cost = flights + hotel × nights + buffer. Excludes consultation fees, visas, and other costs. For information only — not medical, legal, or travel advice.

The bigger picture

Mifepristone is filled about 10.4K times a year under Medicare Part D. At the prices above, that works out to roughly:

Est. annual US spend
$140.5M
If sourced from India
$204.8K
Potential annual savings
$140.3M
−100%

Rough estimate. Based on Medicare Part D prescription volume (not the entire US market) scaled by the representative monthly price — actual totals depend on dose, duration and coverage.